$1.21
-0.07 (-5.47%)
Open$1.25
Previous Close$1.28
Day High$1.26
Day Low$1.20
52W High$5.07
52W Low$0.96
Volume—
Avg Volume177.4K
Market Cap13.40M
P/E Ratio—
EPS$-1.14
SectorBiotechnology
Analyst Ratings
Buy
9 analysts
Price Target
+2,534.7% upside
Current
$1.21
$1.21
Target
$31.88
$31.88
$19.01
$31.88 avg
$45.37
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 205.1K | 969.5K | 5.21M |
| Net Income | -19,983,572 | -84,996,289 | -195,079 |
| Profit Margin | -9,756.5% | -9,268.7% | -3.8% |
| EBITDA | -21,762,866 | -97,706,629 | -244,954 |
| Free Cash Flow | — | — | -167,798 |
| Rev Growth | -78.8% | -78.8% | -0.3% |
| Debt/Equity | — | — | 1.55 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $295.03 | +0.20% | 50.3 | 520.47B |
| AMGN | Amgen Inc | $469.15 | +0.75% | 26.9 | 252.64B |
| GILD | Gilead Sciences Inc | $168.08 | +0.08% | — | 208.95B |
| VRTX | Vertex Pharmaceuticals Inc | $542.98 | +0.81% | 33.9 | 134.82B |
| REGN | Regeneron Pharmaceuticals | $959.96 | +0.47% | 20.4 | 98.38B |
| ALNY | Alnylam Pharmaceuticals Inc | $161.38 | -2.22% | 7.7 | 20.98B |